AstraZeneca (LON: AZN)‘s stock had its “underperform” rating reaffirmed by Credit Suisse in a research note issued on Tuesday. They currently have a $46.07 (3050 GBX) price target on the stock.

AZN has been the subject of a number of other recent research reports. Analysts at Goldman Sachs reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Tuesday. They now have a $50.98 price target on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca in a research note to investors on Wednesday, March 13th. They now have a $45.32 price target on the stock. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca in a research note to investors on Wednesday, March 13th. They now have a $45.32 price target on the stock.

Ten analysts have rated the stock with a sell rating and ten have issued a hold rating to the company. AstraZeneca presently has a consensus rating of “Hold” and a consensus price target of $45.06 (2983 GBX).

Shares of AstraZeneca (LON: AZN) opened at 3042.50 on Tuesday. AstraZeneca has a one year low of GBX 2578.50 and a one year high of GBX 3171.50. The stock’s 50-day moving average is currently GBX 2919.40. The company’s market cap is £37.940 billion.

AstraZeneca PLC (LON: AZN) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.